Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.47) per share for the quarter.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS stock opened at $1.28 on Tuesday. The company has a market cap of $76.90 million, a price-to-earnings ratio of -0.93 and a beta of 0.02. The stock has a 50 day simple moving average of $1.46 and a 200-day simple moving average of $2.06. Acumen Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $4.43. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14.

Insider Transactions at Acumen Pharmaceuticals

In related news, CEO Daniel Joseph Oconnell sold 47,778 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total value of $87,911.52. Following the sale, the chief executive officer now owns 454,707 shares in the company, valued at $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Matt Zuga sold 28,902 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the completion of the sale, the chief financial officer now owns 231,744 shares in the company, valued at approximately $398,599.68. This represents a 11.09 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 131,526 shares of company stock valued at $233,124. Corporate insiders own 7.10% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.